Skip Ribbon Commands Skip to main content
Share This

       Contact:    Geraldine Tan                                                        Paloma Tsai
                        +65 6431 2343                                                      +886 2 21752112

Merial launches Vaxxitek® HVT+IBD in Taiwan


Singapore – 1 December 2013 – The launch of an innovative and advanced vaccine, Vaxxitek® HVT+IBD, took place at Evergreen Plaza Hotel in Tainan, Taiwan on 11th Jul 2013. Merial is proud to introduce the first avian recombinant vaccine, VAXXITEK® HVT+IBD to Taiwan.


“Vaxxitek® HVT+IBD protects poultry against two important immunosuppresive diseases, infectious bursal disease (IBD) and Marek’s disease (MD), which cause huge economic losses to the poultry industry,” said Mr. Dana Chu, the Country Manager of Merial Taiwan. “Since the launch of Vaxxitek HVT+IBD in Brazil in 2006, more than 35 billion doses have been used worldwide. We are excited to bring this vector vaccine technology to Taiwan and we believe that the poultry industry will benefit greatly from it,” he added


Professor Shinn Shyong Tsai from the National PinTung University of Science and Technology, set the scene with a clear and concise introduction to the immune system of chicken.


Dr. Michael Lee, the Regional Avian Technical Director of Merial Asia, made a presentation on the experiences of Vaxxitek® HVT+IBD usage across the globe. “Vaxxitek® HVT+IBD, uses the HVT MD vaccine strain as the vector with a VP2 gene insert from an IBD virus. The expression of the VP2 insert provides protection against IBD, while the HVT vector itself lends protection to Marek’s disease. Vaxxitek® HVT+IBD is proven effective against classic, very virulent and variant strains of the IBD viruses, and can be used in most epidemiological context for IBD control. It is now used across the globe in many major poultry producing countries such as Brazil, US, China, as well as Europe and Asia.”


Discussing the key benefits of using VAXXITEK® HVT+IBD, Dr. Michael Lee made a comparison of Vaxxitek® HVT+IBD with traditional IBD vaccines and highlighted the following advantages:


1. One single shot at the hatchery provides early and prolonged immunity against IBD and MD without the need to revaccinate with other live IBD vaccines.
2. It is simple and convenient to administer the vaccine in the hatchery; in hatcheries that are already using Marek’s disease vaccine, Vaxxitek® HVT+IBD, can be added into the same diluent bag.
3. Unlike live or immune complex IBD vaccines, Vaxxitek® HVT+IBD does not contain any whole live IBD virus that will replicate and damage the bursa. This preserves the bursal integrity and maintains a healthy immune system.
4. One shot offers broad protection against classical, vvIBD and variant strains of IBDV.
5. By avoiding drinking water vaccination in the farm, all the uncertainties or inaccuracies associated with this method of vaccination is eliminated. Vaxxitek® HVT+IBD is given either by the in-ovo or subcutaneous route and this gives better control and precision over the vaccination process.
6. One shot of the vaccine offers dual protection against MD and IBD. “Based on all the key benefits mentioned, we are confident that Vaxxitek® HVT+IBD is currently the most efficacious and safest solution for the control of IBD and MD,” concluded Dr. Lee.


Over 180 participants consisting of mainly colored bird producers and colored bird breeders from the local poultry industry attended the launch.


About Merial

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs more than 6,200 people in more than 150 countries with close to €2 billion of sales.

Merial is a Sanofi company.